Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab (Instituto Vital Brasil)
- Development stage
- Preclinical
- Lead developer
- Bionovis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Rituximab (Instituto Vital Brasil) is a biosimilar monoclonal antibody being developed by Instituto Vital Brasil in collaboration with Bionovis. It is designed to be highly similar to the reference product, Rituxan/MabThera. The drug targets the CD20 antigen, a protein primarily expressed on the surface of B-lymphocytes. Its mechanism of action involves the depletion of B cells through several pathways, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). This biosimilar is intended for the treatment of B-cell malignancies such as non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), as well as various autoimmune disorders. The project is part of a strategic partnership in Brazil to increase local access to high-cost biological medicines.
- Other names
- rituximab biosimilarInstituto Vital Brasil rituximabBionovis rituximab
02
Targets
Beyond the preview
Go deeper on rituximab (Instituto Vital Brasil).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab (Instituto Vital Brasil).